

Index

- AAAQ standard of health care 113, 115
ACCC *see* Australian Competition and Consumer Commission (ACCC)
ACL *see* Australian Consumer Law (ACL)
Action on Smoking and Health (ASH) 43, 52–3, 135
adequate housing 107
ad hoc arbitration procedure 80
Administrative Procedure Act (APA) 233
adult smoking prevalence 249
adult users of e-cigarettes 34–5, 37, 135, 198, 252
advertising 20, 21, 30, 37, 40, 151–2, 209
Advocate General 162, 164, 165, 172–3, 185
 bans 41, 167, 172, 186, 200
 cross-border 156
 domestic 158, 186
 indirect form of 86–7, 97
 proportionality of 172
 restrictions 17, 83
aerosol 7, 56, 72–3, 104, 105
 exposure 60
After Tobacco (Bearman) 24
Agreement on Technical Barriers to Trade (TBT Agreement) 10, 128, 139–43, 145, 147
 likeness under 143
 technical regulation under 140
alcohol 45, 121, 209, 251, 253
aldehydes 54, 55, 60
angioplasty procedures 45–6
Anti-Cancer Council of Victoria 249
anti-smoking media campaigns 252
anti-tobacco legislation 38–9
 costs of 39–40
APA *see* Administrative Procedure Act (APA)
Arnott, Deborah 43
arrhythmia 61
ARTG *see* Australian Register of Therapeutic Goods (ARTG)
ASCEND clinical trial 66, 71
ASH *see* Action on Smoking and Health (ASH)
assessment of Art. 20's compliance with principle of subsidiarity 164–6
attitudes toward ENDS 48, 133, 135
Australian Competition and Consumer Commission (ACCC) 259, 260, 262–3
Australian Consumer Law (ACL) 262
Australian Dental Association 273–4
Australian e-cigarette regulations 35, 249–50
 drugs and poisons regulations 264–5
 electronic cigarettes and personal vaporisers in 269–70
 enforcement of laws 260
 misleading representations 262–3
 nicotine 254–8
 not containing nicotine 259
 oversimplification of laws 254
 personal choice and community impacts 267–8

- political responses to heated tobacco and e-cigarette products 270–72
- possessing, selling, and advertising nicotine 264–5
- precautionary approach 275–6
- public health and medical organization policies on 273–5
- restrictions on sale and public use of 259–60
- seizures of 265
- Senate Select Committee on red tape 268
- TGA Applications 266–7
- tobacco policy 250–54
- Van Heerden* case 261–2
- Vaporised Nicotine Products Bill 2017 268–9
- Australian Register of Therapeutic Goods (ARTG) 257
- authorization 5, 115, 153, 157, 183, 189, 208, 227, 229, 231
- process 4–5, 153
- availability of ENDS 93–4
- bans on ENDS 4, 5, 10, 11, 13–16, 18, 20, 76, 81–88, 126–128, 130–133, 138, 140, 143–145, 148, 157, 168, 208, 211, 213–214, 219, 221, 231–232, 273, 275
- advertising 62, 87, 220, 236, 239, 242, 244, 246, 274
- approach to scientific evidence in WTO dispute settlement system 146–7
- flavors 83, 211, 238,
- general exceptions 143–5
- necessity requirement 145–6
- prohibition of quantitative restrictions 143
- BAT *see* British American Tobacco Plc (BAT)
- Bearman, Peter 24
- behavioral risk factors 120
- best interests of the child (BIC) 119–20
- BIC *see* best interests of the child (BIC)
- Big Sugar companies 42
- Big Tobacco 9, 21, 28, 43–4, 49, 222, 271,
- as pharmaceutical company 42–4
- relegitimization of 39–42
- technological innovation 30
- biomarkers 57
- Bonsack machine 29
- Bower, Joseph 29
- Brandt, Allan M. 9, 22
- Branston, J.R. 40
- British American Tobacco Plc (BAT) 33, 35, 43
- British Medical Association 38
- Bromberg, Marilyn 12
- bronchiolitis 55
- Calantzopoulos, André 42
- Campaign for Tobacco-Free Kids 21, 27, 243
- cancer 1, 3, 31, 44–5, 54, 69, 72, 197
- Capewell, Simon 49
- carbon monoxide 1, 58, 66, 132
- carcinogens 15, 53, 57, 61, 110, 167, 263, 266
- CESCR *see* Committee on Economic, Social and Cultural Rights (CESCR)
- cessation 1, 3, 40, 123, 124, 153, 156, 158, 193, 199, 210, 212
- aids 12, 37, 38, 40, 47, 51–3
- e-cigarettes featuring 5
- medicine demands 47
- products 91
- smoking 64–70, 110

- sociodemographic determinants of 52
- of tobacco use 86
- Chan, Margaret 37
- childproof packaging 169–71
- child rights framework 118
- China 27
 - conventional tobacco products 220
 - domestic consumption 215
 - e-cigarettes in 6, 11
 - global cigarette production 215
 - Maternal Child and Community Health Division 217
 - regulation in 215–19
 - State Tobacco Monopoly Administration (STMA) 216–18
 - TFDA approval 220
 - tobacco control in 217–18
 - tobacco regulatory 216
- China National Tobacco Corporation (CNTC) 216–18
- Christensen, Clayton 29
- chronic obstructive pulmonary disease (COPD) 59
 - medical records of 59
- cigalikes 67, 128, 132
- cigarettes
 - components of 31
 - demand and supply of 26
 - denormalization of *see* de-normalization strategies
 - design and composition of 30
 - domestic production of 131–2
 - filters 31, 33
 - nicotine levels in 49
 - packs 221, 228, 235, 249–50
 - smoke yield information 250
- cigarettes smoked per day (CPD) 69–70
- CJEU *see* Court of Justice of the European Union (CJEU)
- classification of e-cigarettes 4, 77–8, 94–5
- cloud chasing 62
- CNTC *see* China National Tobacco Corporation (CNTC)
- combustible cigarettes 3, 6, 9, 11, 29, 30, 36, 34–5, 42–3, 44, 45, 46, 48, 51 56, 61, 62, 108, 110–11, 115, 116, 118, 123, 132–9, 169, 173, 198, 204, 205, 212–13, 219, 224, 229, 231
 - traditional 49, 61
 - for children 45
 - denormalization *see* de-normalization strategies
 - design of 99–100
 - likelihood of 116–17
 - nicotine consumption via 110
 - production of 49
 - secondhand smoke caused by 45, 60, 115, 200
 - smoking 99
 - THPA regulations on 201
 - use of 116
- Committee on Economic, Social and Cultural Rights (CESCR) 106, 107–8, 111, 113
- Conference of the Parties (COP) 5, 9, 16, 77, 80–7, 89, 92–98, 126, 168–169, 200, 218
 - decisions of 94
 - meetings 84, 88
 - regulatory measures 95
- constituents, ENDS
 - flavors 55–6, 67, 128
 - glycerin 54–5
 - nicotine 53–4, 67, 128
 - propylene glycol (PG) 6, 54–5, 67, 128
- consumer
 - good 4, 5, 17, 27, 30, 31, 83, 87, 95, 225, 238, 268

- protection rules 152–3
- surveys 136
- tastes 135, 137
- controversy over e-cigarettes 1–3, 39
- conventional cigarettes *see* combustible cigarettes
 - consumption 221–2
 - smoking rate 198
- conventional smoking 3, 197, 213–14
- Convention on the Rights of the Child (CRC)
 - child health and development in 117–19
 - Committee 120, 121
 - framework 120
- COP *see* Conference of the Parties (COP)
- COPD *see* chronic obstructive pulmonary disease (COPD)
- corporate responsibility 40–41
- Court of Justice of the European Union (CJEU) 10, 16, 150–151, 160, 162, 164–168, 172–3, 176, 187, 192,
 - case law 184–8
 - role of 168
- CPD *see* cigarettes smoked per day (CPD)
- CPED *see* cross-price elasticity of demand (CPED)
- CRC *see* Convention on the Rights of the Child (CRC)
- creative destruction 129
- cross-price elasticity of demand (CPED) 138
- deception 26, 47
- Deeming Rule 233–8, 240–41
- de-normalization strategies 117
- dependence 51, 86, 99, 100, 111, 113, 117, 221, 250, 251, 277
- diacetyl 1, 6, 55
- disadvantaged population 70–71
- discretion 17, 87, 90, 95, 165, 166, 168, 171, 183, 187, 188, 193, 245
- discrimination 10, 18, 102, 126–128, 130–135, 138, 139–140, 145, 148, 170–171, 187
- dispute settlement 80, 91–2, 132, 146, 148
- disruptive innovation 29–30, 47
 - industrial strategies reminiscent of 29
 - proto-ENDS 32–3
 - search of “safer” cigarette 30–32
- disruptive technology *see* disruptive innovation
- Doll & Hill 30
- domestic advertising 158
- dry puff 55, 60
- Eastern Bloc 31
- ECLAT trial 59, 66
- effectiveness 13, 39, 47, 52, 65, 66, 67–8, 71, 82, 93, 108, 146, 167,
 - effective regulatory measures 79–80
- EHTPs *see* electronically heated tobacco products (EHTPs)
- electric smoking systems 7
- electronically heated tobacco products (EHTPs) 127, 129, 136–7
- electronic non-nicotine delivery systems (ENNDS) 83, 86, 95, 200, 202, 204–15, 222
- e-liquids 1, 5, 6, 54, 55, 68, 73, 105
 - chemicals 104
 - flavoring *see* flavors/flavoring
 - nicotine in 6, 155
 - solutions 56
- Elusion Australia Limited 263
- endgame 9, 24, 50, 76
- Endicott, Kenneth 31
- ENDS market, e-cigarettes market 44, 128–30, 209, 224, 232

- English Stop Smoking Services 64
- environmental health protection
obligations 107
- equal treatment 19, 132, 169–73
- EU *see* European Union (EU)
- EU law, vaping and precautionary
principle in 175–6, 188–93
- actual risks 177
 - CJEU 184–8, 192
 - economic harmonization 188
 - e-liquid flavoring 190
 - irreversible threats 180
 - normalization effect 185
 - potential risks 175–6, 180
 - and practice 179–84
 - precautionary measures 193
 - Rio Declaration 1992 178, 180
 - risk society 177
 - scientific certainty 187–8, 192
 - scientific uncertainty 180
 - surveillance and control tasks 189
 - TPD 184–90, 192
 - traditional smoking 192
 - Treaty on the Functioning of the
European Union (TFEU) 180
 - Wingspread Statement 179
- EU regime for e-cigarettes 155–60
- genesis of directive and legislative
process 151–5
- Eurobarometer study 64, 70
- European Commission 15, 152, 158,
161–3, 165, 182, 190
- European Parliament 150, 151, 154, 155,
165
- European Union (EU)
- Charter 18, 160, 171–2, 187, 189
 - Directives on Medicinal Products
(MPD) 114, 154, 156
 - fundamental freedoms 171–3
 - internal market 10–11, 173
 - sui generis* model 4, 5 10, 11, 13, 86
154, 174, 185
 - ex-smokers 59, 64–5, 67, 69
 - Fagerström, Karl-Olov 36
 - FCTC *see* Framework Convention on
Tobacco Control (FCTC)
 - Ferro, Giancarlo A. 10
 - filtered cigarettes 32
 - flavors/flavoring 30–31, 55–6, 61–2,
67–8, 83, 122, 128, 129, 155, 158,
159, 170, 196, 201, 211, 214
 - in e-liquids 55–6, 122
 - purpose of regulating 141 - Foltea, Marina 10
 - Food and Drugs Administration (FDA)
14–16, 19, 21, 159, 224–247
 - formaldehyde 54, 55, 60
 - Foundation for a Smoke-Free World
(FSFW) 41–2, 44
 - Framework Convention on Tobacco
Control (FCTC) 5, 9, 16, 17,
26–7, 40, 76–8, 98, 126, 152, 155,
167, 168, 169, 184–5, 197, 200,
211, 216, 217, 218
 - applicability to e-cigarettes 85
 - binding interpretations of 94
 - COP 5, 9, 16, 17, 59, 77, 81–5, 94,
168–9, 200, 218
 - description of 78–80
 - disciplines of 9, 77
 - objective of 91
 - obligations 79, 84, 87, 93
 - optimal regulatory strategy 77
 - quasi-authoritative interpretation
of 92
 - Secretariat 84, 85–7 - freebase e-liquids 6
 - freedom to conduct a business 19, 171,
172
 - FSFW *see* Foundation for a Smoke-Free
World (FSFW)
 - fundamental freedom 19, 171–3

- Gartner, Coral 12
- gateway effect 3, 9, 13, 62, 63, 93, 99, 117, 121, 125, 144, 157, 167
- GATT *see* General Agreement on Tariffs and Trade (GATT)
- General Agreement on Tariffs and Trade (GATT) 10, 128, 131–40, 146–7
national treatment 131–139, 143
- general exception 143–145
- Gillespie, David 270
- Glantz, Stanton 13, 37
- Gispén, Marie Elske C. 9, 17
- GlaxoSmithKline 154
- Global Forum on Nicotine 43
- glycerin 54–5
- Harmonized System (HS) 137
- harm reduction 30, 40, 68–70, 199
defined 69
programs 111–13
tobacco 49, 246–8
vulnerable and disadvantaged populations 70–71
- Harm Reduction Coalition 109
- health adversity, nicotine and 53
- health claims *see* health-related claims
- health effects of ENDS
general population 57–8
passive exposure 60–61
pre-existing physical health conditions 59–60
safety profile of 61–2
- health-related claims 81, 82, 83, 114, 133–4, 204, 274
- health warnings 83, 156, 170, 200, 201, 208, 233, 235, 249, 252, 270, 274
- heat-not-burn (HNB) tobacco 7, 28, 43, 45, 77
- Herbeć, Aleksandra 9
- high-resolution computed tomography (HRCT) 58
- HNB tobacco *see* heat-not-burn (HNB) tobacco
- Hon Lik 6, 27–9, 32
- HRCT *see* high-resolution computed tomography (HRCT)
- human rights approach, e-cigarette regulation 9, 99–125
access to information and right to health 108–9
as gateway product 116–17
child and right to life, survival and development 119–20
child health and development in CRC 117–19
right to health, information, and participation in decision-making 120–22
as harmful device 104–5
as harm reduction tool 109–11
international and regional 104
protection against secondhand (tobacco) smoke and right to health 115–16
regulatory approaches under the right to health 113–15
and tobacco control 102–4
- Hungary 159
- Hunt, Greg 271
- hydrogen cyanide 1
- ICCPR *see* International Covenant on Civil and Political Rights (ICCPR)
- ICESCR *see* International Covenant on Economic, Social, and Cultural Rights (ICESCR)
- ILC *see* International Law Commission (ILC)
- Imperial Tobacco 28, 224
- industry *see* tobacco industry
- inhalation, nicotine 2
- intellectual property rights 172–3

- internal market *see* European Union (EU)
- International Covenant on Civil and Political Rights (ICCPR) 102
- International Covenant on Economic, Social, and Cultural Rights (ICESCR) 101, 105, 106, 111, 120–21
- international law 87, 88, 96, 101, 105, 176, 177–180
- International Law Commission (ILC) 88
- international trade 18, 78, 127, 144, 146, 148,
- interpretation 17, 90–95, 114, 120, 130, 143, 186, 203, 213–15, 258, 270
- interpretative declaration 88–90
- IQOS 7, 21, 43, 231, 270
- JUUL Labs, Inc. 21–2, 35, 239, 240
- Kandel, Denise 116
- Kandel, Eric 116
- Kovacevic, Patricia I. 11, 13
- Kulik, M. C. 46
- laissez-faire approach 11, 81–2, 87
- Leyonhjelm, David 268, 271
- Ley, Sussan 271
- liability 4, 218, 263
- likeness 130, 132
 - consumers' tastes and preferences 135–7
 - criteria 138–40
 - determination of 141–2
 - end use 134–5
 - physical properties 132–4
 - preliminary conclusions 139
 - tariff classification 137–8
 - useful indicator of 133
- like products 139–40
- Little, Clarence Cook 41
- Lin, Ching-Fu 11, 13
- long-term effect xix, 3, 38, 57, 73, 171, 174, 206
- Lo, Mao-Wei 11,
- low tar cigarette 12, 249, 250, 278
- malfeasance 26
- manufacturers 27, 31, 56, 108, 122, 157, 169, 176, 183, 186, 200, 204, 206, 209, 212–13, 219, 221, 224–5, 237
- markets 28, 34–5, 44, 93, 129, 150, 224
- MarkTen e-cigarettes 33
- MEAs *see* multilateral environmental agreements (MEAs)
- media 22, 28, 45, 71–3, 118, 121, 122
- Medicines Evaluation Board of the Netherlands 114
- menthol cigarettes 141, 238
- Mercurio, Bryan 10
- methadone 113
- mimic smoking 86, 91, 128, 132, 191, 204, 213, 214
- Modified Risk Tobacco Product (MRTP) 228–30, 241, 244
- mods 6
- MRTP *see* Modified Risk Tobacco Product (MRTP)
- multilateral environmental agreements (MEAs) 94
- Myers, Matthew 27
- National Drugs and Poisons Scheduling Committee 258, 266
- National Drug Strategy (NDS) 250, 253
- National Health and Medical Research Council (NHMRC) 249, 269
- National Health Interview Survey (NHIS) 59
- National Preventative Health Strategy 252
- National Preventative Health Taskforce (NPHT) 251

- National Tobacco Strategy (NTS) 250
 national treatment principle 131–143
 NDS *see* National Drug Strategy (NDS)
 necessity 145–6
 New Nicotine Alliance 267
 New South Wales, ban of e-cigarettes 260
 new tobacco product 227, 234, 236
 Next Generation (Nicotine) Products (NGPs) 28, 46–7
 NHIS *see* National Health Interview Survey (NHIS)
 NHMRC *see* National Health and Medical Research Council (NHMRC)
 Nicolosi, Costanza 10
 Nicopure litigation 240–45
 nicotine 2, 53–4
 addiction 1, 3, 13, 17, 36, 47, 86–8, 95, 159, 197, 205
 aerosol devices 32
 biomarkers of 57
 classification of 256–7
 containing products 108, 266
 delivery systems 250–51
 dependence 117
 in e-liquids 6, 155, 255
 forms of 6
 and health adversity 53
 inhalation 2
 regulation 247
 seizures of 265
 nicotine replacement therapy (NRT) 32, 36, 38, 53, 54, 61, 109, 111
 products 114, 153
 use of 69
 users 57
 non-discrimination 130–32, 139, 140, 171, 178, 189
 non-governmental organization 179, 232, 233, 243
 non-smokers 12, 37, 49–50, 62, 93, 97, 137, 156, 192, 209, 213, 215, 252
 non-substantial equivalence (NSE) 229
 non-user 61, 83, 115, 230, 237, 268
 notification 154, 156, 157, 167, 171, 174, 186, 188, 189, 227, 270
 NPHT *see* National Preventative Health Taskforce (NPHT)
 NRT *see* nicotine replacement therapy (NRT)
 NSE *see* non-substantial equivalence (NSE)
 NTS *see* National Tobacco Strategy (NTS)
 Obama, Barack 226
 passive exposure, ENDS 60–61
 passive smoking 40, 45, 60–61
 personal use 208
 PG *see* propylene glycol (PG)
 pharmaceutical companies 14–15, 42–5
 pharmaceutical model 13, 153, 154, 210
 pharmaceutical product 4, 81, 137, 203, 204, 206, 208, 216, 218–20
 pharmacotherapy 51
 for smoking cessation 51
 traditional 52
 PHE *see* Public Health England (PHE)
 Philip Morris 32, 33, 41–4
 Project Sunrise 47
 Philip Morris International (PMI) IQOS device, 231
 Pillbox 167, 172–3, 187
 PMTAs *see* premarket tobacco product authorization (PMTAs)
 pod-based systems 6–7
 poison 4, 5, 15, 104, 171, 252, 254–9, 264–70
 Poland 25, 35, 39, 43, 152
 Polish Tobacco Monopoly 31

- precautionary principle xix, 10, 47, 49, 101, 167, 175–6, 182, 188–93, 225, 232, 250, 275–6
- actual risks 177
 - application of 183
 - CJEU 184–8, 192
 - decision-making process 182
 - de facto substantive evaluation 193
 - defined 181
 - economic harmonization 188
 - e-liquid flavoring 190
 - ENDS 185–6, 189
 - environmental degradation 178–9
 - European regulatory process 181
 - irreversible threats 180
 - normalization effect 185
 - political nature of 184
 - potential risks 175–6, 180
 - and practice 179–84
 - precautionary measures 193
 - precautionary principle in
 - international law 176–9
 - regular smoking 175
 - regulatory intervention 188
 - Rio Declaration 1992 178, 180
 - risk society 177
 - scientific certainty 187–8, 192
 - scientific uncertainty 180
 - scope of 183
 - surveillance and control tasks 189
 - TPD 184–90, 192
 - traditional smoking 192
 - Treaty on the Functioning of the
 - European Union (TFEU) 180
 - Wingspread Statement 179
- premarket review 227, 242
- premarket tobacco product authorization (PMTAs) 230, 231, 236
- prevention 82, 83, 146, 177, 191, 200, 225–231
- principle of legal reservation 214
- procedural dimension of the principle of subsidiarity 162–4
- prohibition of quantitative restrictions 143
- Project Sunrise 47
- proportionality 18, 124, 160–1, 166–7, 169, 172, 173, 182, 186–8, 193, 276
- directive and principle of 166–9
 - principle of 166–9, 172
 - principles of 161
- propylene glycol (PG) 6, 54–5
- prosecution 260, 264–5, 268
- proto-ENDS 32–3
- public health 28, 40, 167, 172, 174, 176, 181, 183, 187, 188, 192, 198
- progress 36, 49
 - protection 76
 - recommendations 46
 - regulators 47
 - risks of 206, 275
 - statistics in 44–5
- public health community 41, 42, 45
- implications for 48–9
- Public Health England (PHE) 36, 67, 71, 110
- public places 20, 25, 34, 79, 83, 86, 158, 201, 203, 207–209, 212, 220
- public smoking bans *see* smoking ban
- Pudło, Anna 10, 13
- Queensland Health 257
- racial discrimination 102
- randomized controlled trials (RCT) 53–4, 58, 65–6, 69, 73
- ratification 78, 80, 216
- RCT *see* randomized controlled trials (RCT)
- regulatory approaches 3–4, 11, 12, 14, 18, 82, 99, 101, 112, 113, 115, 122, 124, 152, 155, 203–5

- Regulatory Consultation on the Safety of Electronic Nicotine Delivery Systems 81
- rehabilitative services 113
- renormalization 3, 40, 44, 82, 97, 144, 171, 174
- research in media 71–3
- reservation 88, 214
- rights of the child 101, 107
- right to health
 - access to information and 108–9
 - harm under 105–6
 - information, and participation in decision-making 120–22
 - programs under 111–13
 - protection against secondhand (tobacco) smoke and 115–16
 - regulatory approaches under 113–15
 - vapor as part of 107–8
- Roberts, Malcolm 268–9
- Roxon, Nicola 251, 271
- Russell, Michael 53
- safer cigarette 31, 32
- sales ban *see* bans on ENDS
- scientific uncertainty, level of 168
- Scotland 63
- secondhand smoking *see* passive smoking
 - protection against 115–16
- seizures 265
- Senate Community Affairs Legislation Committee 268–9
- Senate Economics References Committee 267–8
- SE premarket authorization pathway 229
- Shahab, Lion 57
- short-term effect 46, 57, 66
- Skinner, Jillian 265
- SKUs *see* stock keeping units (SKUs)
- Smith, Charlie A. 9
- smoke-free places 36, 51, 107, 118, 136, 158, 186, 201, 210, 260, 274
- smokeless tobacco 61, 69, 152, 218, 227, 229, 253
- smokers/smoking 1–3, 49, 50–5, 57–9, 62
 - addictive nature of 25, 41
 - conversion rates 34
 - health effects of 73
 - mass popularity of 25
 - quit 43
 - rates 24
 - reduction, levels of 71
 - ritual of 134
 - secondhand 40
 - sensory feel of 128–9
 - social acceptability of 25
 - to vaping 57
- smoking bans 25, 49, 51, 107, 108, 148, 207, 246, 252, 269,
 - bans 25
 - in private spaces 107
 - in public spaces 107
- smoking cessation 64–73, 79, 81–2, 84, 86–8, 91, 99, 109–12, 123, 135
- ENDS effectiveness 67–8
- interventions 70
- meta-analyses 66–7
- observational studies 64–5
- pharmacotherapy for 51
- randomized controlled trials (RCT) 65–6
- use and 64
- smoking prevalence 24–7, 36, 39, 50, 63–4, 70, 96, 197, 249, 274
- socio-economic disparity in 249
- Smoking Toolkit Study (STS) 64
- Sottera* litigation 232
- sponsorship
 - activities 158
 - and advertising 151–2

- Standard for the Uniform Scheduling of Medicines and Poisons 254
- standard of review 147
- STMA *see* State Tobacco Monopoly Administration (STMA)
- stock-keeping units (SKUs) 236, 237, 246
- STS *see* Smoking Toolkit Study (STS)
- subsidiarity 18, 160–6, 173, 187
 dimensions 161
 nature of principle of 161–4
 principle of 164–6
- substances, scheduling of 255
- substitutes 4, 109, 110, 113, 124, 136, 138, 148, 198, 201, 202, 250, 252
- sui generis* category *see sui generis* model
- Sweanor, D. 40
- Taiwan, e-cigarette regulation in 197–200
 advertising (bans) 208
 banning from smoking 200–201
 battery-powered devices 197
 conventional cigarettes 213
 consumption 221–2
 smoking rate 198
 conventional tobacco control laws 199
 drugs and drug delivery devices 208–9
 ENDS/ENNDS 204–15, 222
 harm reduction 199
 Health Promotion Administration (HPA) 204, 213, 221
 legal definition of tobacco products 202–3
 level of obligations 210
 non-tobacco products 213–14
 Pharmaceutical Affairs Act (PAA) 204, 206–8
 pharmaceutical regulatory framework 210
 precautionary principle 205
 public opinion and policy-makers 221
 regulatory approach toward 203–4
 regulatory framework and laws 222
 smoke-free policies 213
 smoking prevalence 197
 tobacco control measures 201–2
 Tobacco Control Regulation 200–201
 Tobacco Hazards Prevention Act (THPA) 200–203, 205–7, 213–14
- Taiwan Food, Drug and Cosmetic Administration (TFDA) 203
- tank systems 128
- tar 1, 12, 31, 32, 53, 238, 249, 250, 278
- tariff classification 132, 133, 137–8
- Tasmania 260
- tax 18, 20, 41, 143, 158, 190–91, 200, 201, 208, 216, 246, 274, 275
- TBT Agreement, non-discrimination under 139–43
- TEU *see* Treaty on European Union (TEU)
- TFDA *see* Taiwan Food, Drug and Cosmetic Administration (TFDA)
- TFEU *see* Treaty on the Functioning of the European Union (TFEU)
- TGA *see* Therapeutic Goods Administration (TGA)
- therapeutic claim 4, 13, 17, 114, 115, 220, 232, 254
- Therapeutic Goods Administration (TGA) 257
- therapy 53, 153
- TIRC *see* Tobacco Industry Research Committee (TIRC)
- tobacco 4
 addictive properties to 52

- cigarettes 54
- combustion of 7
- companies 29
- consumption 87–8
- control community 9, 36–8, 44
- control summits 28
- flavors 90–91
- harm reduction 49
- health effects of 45
- industry operations 78
- products 3
- regulation, traditional concepts of 48
- smokers/smoking 44, 50, 65
- use, prevalence of 93
- Tobacco Act 1987 (VIC) 262
- tobacco and harmonization 152–3, 188, 194
- Tobacco and Other Smoking Products Act 1998 (QLD) 259, 261
- Tobacco and Other Smoking Products Regulation 2010 (QLD) 259
- tobacco control 24–6, 50–52, 107, 184–5, 197, 199–203
 - approach to 26
 - challenges for 26
 - disruptive innovation 28, 29–30, 33, 48
 - proto-ENDS 32–3
 - search of “safer” cigarette 30–32
- e-cigarettes 27–8, 33–6
- ENDS constituents *see* constituents, ENDS
 - flavors 55–6
 - glycerin 54–5
 - nicotine 53–4
 - propylene glycol (PG) 54–5
- ENDS use in adults 52–3
- factors which Affect ENDS
 - effectiveness 67–8
- harm reduction 68–70
 - vulnerable and disadvantaged populations 70–71
- health effects of ENDS
 - general population 57–8
 - passive exposure 60–61
 - pre-existing physical health conditions 59–60
 - safety profile of 61–2
- history of 41
- misinterpretation of ENDS research 71–3
- relegitimization of Big Tobacco 39–44
- scholars 37
- smoking cessation 64–7
- in times of scientific uncertainty 44–6
 - implications for policy 46–8
 - implications for public health community 48–9
- Tobacco Control Community 36–7
- Tobacco Control Act 210, 225–31
- tobacco industry 14, 25, 26, 29–33, 37, 38, 40–44, 47–50, 62, 78, 79, 93, 97, 103, 108, 121, 152, 199, 216, 219, 225, 226, 229, 250
- Tobacco Industry Research Committee (TIRC) 41
- tobacco market 151–2
- tobacco products 1, 3–4, 7, 10, 13, 21, 35, 76, 77, 79, 81–7, 89–95, 104, 106, 109, 122, 126, 127, 133–9, 156, 169–72, 185, 189, 191, 194, 197, 200–204, 207, 211–14, 218, 219
 - definition of 90, 95
 - labeling requirements for 170
 - legal definition of 203
- Tobacco Products Control Act 2006 (WA) 261

- Tobacco Products Directive (TPD) 10, 150–6, 158–60, 165–74, 184–90, 192
 - Art. 20 of 169–72
 - ban on cross-border advertising 156–7
 - ban on flavors in tobacco products 170
 - emission levels of nicotine 170–71
 - objectives of 173
 - provisions of 158, 159, 165–6, 168
- TPD *see* Tobacco Products Directive (TPD)
- traditional cigarettes *see* combustible cigarettes
- traditional pharmacotherapy 52
- traditional tobacco, incarnation of 76
- transnational tobacco companies (TTCs) 25–6, 28, 30, 35, 36, 39–40 *see* also Big Tobacco and tobacco industry
- Treaty of Lisbon 160, 166
- Treaty on European Union (TEU) 160, 161
- Treaty on the Functioning of the European Union (TFEU) 160, 163–4, 180, 183, 189
- TTCs *see* transnational tobacco companies (TTCs)
- UDHR *see* Universal Declaration of Human Rights (UDHR)
- UK 14, 15, 20, 22, 30, 33, 34, 36, 38, 63, 69, 70, 72
- UN *see* United Nations (UN)
- uncertainty, scientific 44–6
 - implications for policy 46–8
 - implications for public health community 48–9
- United Nations (UN)
 - Charter of 102
 - human rights treaties 103
- United Nations Treaty Collection 88
- Universal Declaration of Human Rights (UDHR) 102
- US law 224–6
 - Center for Tobacco Products (CTP) 226
 - Cole–Bishop Amendment 243
 - covered tobacco products 235
 - Deeming Rule 233–8, 240–241
 - Family Smoking Prevention 225
 - family smoking prevention and tobacco control act 225–31
 - FDA jurisdiction 231–40
 - flavor and advertising bans 242–3
 - Modified Risk Tobacco Product (MRTP) application scheme 228
 - Nicopure litigation 241–5
 - PMTA 240
 - premarket authorization pathways 227
 - public health community 38
 - Regulatory Flexibility Act 242
 - SE applications 228–9
 - Tobacco Control Act (TCA) 225
 - tobacco harm reduction 246–8
 - tobacco product 226
 - tobacco products 240
 - types of tobacco products 227
- US Tobacco Control Act 11–12
- Van Heerden* case 261–2
- vape/vaping 27, 54, 55, 57, 59–62, 71, 83, 91, 117, 120, 129, 134, 136, 175, 176–95
 - availability of 62
 - causes 60
 - device 239
 - pens 6
 - product 136
 - shops 60
 - on smoking 117

- smoking to 57
- vapor, environmental health and protection against 1, 7, 54, 107–8, 213
- Vaporised Nicotine Products Bill 2017 268–9
- VCLT *see* Vienna Convention on the Law of Treaties (VCLT)
- vegetable glycerin (VG) 6, 67–8
- Veraldi, Jacquelyn D. 17
- VG *see* vegetable glycerin (VG)
- Victoria 260
- Vienna Convention on the Law of Treaties (VCLT) 88–9, 90, 94
- vulnerable populations 70–71

- Watt, Murray 268
- WCO *see* World Custom Organization (WCO)
- WHA *see* World Health Assembly (WHA)
- WHO *see* World Health Organization (WHO)
- Wilson, Tim 269
- workplace 25, 79
- World Custom Organization (WCO) 137
- World Health Assembly (WHA) 26, 78
- World Health Organization (WHO) 5, 27, 37, 41, 111, 209, 213, 217, 252

- auspices of 78
- Framework Convention on Tobacco Control (FCTC) 5, 126, 152, 184–5, 197, 217
- List of Essential Medicines 112
- report 82, 84
- Study Group on Tobacco Product Regulation 154
- Tobacco Free Initiative 81
- World Trade Organization (WTO) 10, 126
- agreements 127
- discrimination analysis 138
- Dispute Settlement System 146–7
- features of 130
- non-discrimination rules 131
- obligations of 129, 130
- panel/Appellate Body 134
- WTO *see* World Trade Organization (WTO)
- WTO law, non-discrimination under 130–31
- Wu, Chuan-Feng 11, 13
- Wynder, Ernst 31
- Wynder & Graham 30

- Yach, Derek 41

- Zatoński, Mateusz 9
- Zimmerman, Trent 269